Results 31 to 40 of about 2,101 (161)
Медицинский совет, 2021 There has been clear progress in rheumatology in recent decades with the introduction of genetically engineered biological drugs (GEBDs) as well as targeted baseline anti-inflammatory drugs, which include Janus kinase inhibitors (i-JAKs). To date, i-JAKs
B. S. Belov +3 more
doaj +1 more source
Arthritis Research & Therapy, 2022 Background The effects of filgotinib on patient-reported outcomes (PROs) from 3 trials in patients with active rheumatoid arthritis were investigated.
Clifton O. Bingham +7 more
doaj +1 more source
Patient Preference and Adherence, 2023 Yoshiya Tanaka,1 Mark C Genovese,2,3 Hironori Matsushima4 1The First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health Japan, Kitakyushu, Japan; 2Division of Immunology and Rheumatology, Stanford ...
Tanaka Y, Genovese MC, Matsushima H
doaj
RMD OpenObjectives DARWIN 3 (ClinicalTrials.gov: NCT02065700) assessed the safety and efficacy of filgotinib in a long-term extension (LTE) of two phase II randomised controlled rheumatoid arthritis (RA) trials.Methods Eligible patients completing the 24-week ...
Arthur Kavanaugh +13 more
doaj +1 more source
Arthritis &Rheumatology, EarlyView.Objective Osteoporosis causes fractures that further increase the disease burden of rheumatoid arthritis (RA); however, osteoporosis treatment rates remain low. Although several studies have reported that biologic or targeted synthetic disease‐modifying antirheumatic drugs (b/tsDMARDs) can prevent or improve osteoporosis in RA, our large‐scale, real ...
Takafumi Aritomi +30 more
wiley +1 more source
Efficacy and Safety of Biologics and Small Molecule Drugs in the Treatment of Ulcerative Colitis: a Network Meta-analysis [PDF]
Zhongguo quanke yixueBackground Ulcerative colitis (UC) is a persistent immune-mediated inflammatory bowel disease characterized by chronic relapses and remissions. The management of UC remains a subject of contention, particularly as approximately half of the patients ...
TAN Shufa, ZHANG Leichang, GAO Qiangqiang, OU Yan, HUANG Shuilan
doaj +1 more source
Clinical Pharmacology &Therapeutics, EarlyView.We evaluated whether concomitant 5‐aminosalicylic acid (5‐ASA) influences clinical remission in patients with ulcerative colitis (UC) receiving Janus kinase inhibitors (JAKi). In this retrospective, multicenter cohort study, UC patients receiving tofacitinib (n = 181), upadacitinib (n = 313), or filgotinib (n = 139) were included.
Antonio Tursi +100 more
wiley +1 more source
Carbon Footprint of Antibody‐Based Drugs and Biologics Using Hybrid Life Cycle Assessment
Clinical Pharmacology &Therapeutics, EarlyView.Life cycle assessment of monoclonal antibodies. Biological engineering has emerged since the 1980s as one of the most efficient technologies to develop new medicines. The monoclonal antibody platform is the most widely used, representing about 15–20% of drug sales.
Sébastien Taillemite +3 more
wiley +1 more source
HPV‐6 Positive Eruptive Verruca Vulgaris After Upadacitinib Initiation for Severe Atopic Dermatitis
JEADV Clinical Practice, EarlyView.ABSTRACT Oral JAK‐1 inhibitors for atopic dermatitis (AD) are associated with an increased risk of cutaneous viral infections, particularly herpes zoster. Emerging case reports further suggest a link to eruptive human papillomavirus (HPV) disease. A 23‐year‐old transgender man (female‐to‐male) with severe AD developed a rapidly disseminating eruption ...
Mohammed Shanshal +2 more
wiley +1 more source
Drugs in ContextBackground: Filgotinib, an oral Janus kinase 1 preferential inhibitor, has been shown to be an effective treatment for ulcerative colitis (UC) in pre-registration studies.
David Young +21 more
doaj +1 more source